Business Context and Reporting Period
This Form 8-K was filed by Oramed Pharmaceuticals Inc. on June 8, 2017, reporting an event that occurred on June 5, 2017. The Company is a Delaware corporation with principal executive offices in Jerusalem, Israel.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a corporate governance event rather than financial performance.
Material Changes
The Board of Directors authorized the Company to apply for the listing of its common stock ($0.012 par value) on the Tel-Aviv Stock Exchange (TASE). The Company expects trading on the TASE to commence during the fourth quarter of the fiscal year ending August 31, 2017, pending approval from the Israel Securities Authority (ISA). The stock will continue to trade on The NASDAQ Stock Market LLC under the symbol "ORMP".
Guidance, Outlook, and Risks
- Outlook: Management anticipates TASE listing in Q4 of the fiscal year ending August 31, 2017.
- Risks and Contingencies: The filing includes a warning that the Company may not receive approval from the ISA. Consequently, the commencement of trading on the TASE may be delayed or may not occur at all.
- Forward-Looking Statements: The report contains forward-looking statements based on present intent and beliefs, which are not guaranteed to occur.
Investor Verification Checklist
- Confirm whether the Israel Securities Authority (ISA) has granted approval for the TASE listing.
- Verify the actual commencement date of trading on the TASE against the Q4 2017 expectation.
- Monitor continued trading status on NASDAQ under the symbol "ORMP".